Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brian Gastman

Showing results (51-60 of 70) with videos related to

Pageof 7
Sort By:
Transplantation and Cellular Therapy|May 7, 2026
Real-World, Evidence-Based, Retrospective Study of Patients Infused with Commercially Released Lifileucel for Advanced MelanomaLilit Karapetyan, Justin Moser, Barbara T Ma, et al.
Science Immunology|May 17, 2024
LRIG1 engages ligand VISTA and impairs tumor-specific CD8<sup>+</sup> T cell responsesHieu Minh Ta, Dia Roy, Keman Zhang, et al.
The Journal of Experimental Medicine|September 9, 2015
A novel IL-17 signaling pathway controlling keratinocyte proliferation and tumorigenesis via the TRAF4-ERK5 axisLing Wu, Xing Chen, Junjie Zhao, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 2, 2025
Long-Term Efficacy and Safety of Lifileucel Tumor-Infiltrating Lymphocyte Cell Therapy in Patients With Advanced Melanoma: A 5-Year Analysis of the C-144-01 StudyTheresa Medina, Jason A Chesney, Harriet M Kluger, et al.
Journal of the American Academy of Dermatology|March 21, 2024
Germline cancer susceptibility in individuals with melanomaPauline Funchain, Ying Ni, Brandie Heald, et al.
Nature Medicine|October 16, 2023
Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trialJohn M Kirkwood, Michele Del Vecchio, Jeffrey Weber, et al.
Journal for Immunotherapy of Cancer|August 25, 2025
Efficacy and safety of one-time autologous tumor-infiltrating lymphocyte cell therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinomaRobert L Ferris, Rom S Leidner, Christine H Chung, et al.
Future Oncology (London, England)|February 23, 2024
Plain language summary of the CheckMate 76K study results: nivolumab given after stage 2B/2C melanoma is removed by surgeryJohn M Kirkwood, Michele Del Vecchio, Jeffrey Weber, et al.
Transplantation and Cellular Therapy|February 28, 2026
Advancing Cell Therapies for Solid Tumors: A Pathway to Overcome Biological, Operational, and Regulatory HurdlesKedar Kirtane, Michael Kalos, Rocky Billups, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 28, 2025
A Phase I, First-in-Human, Dose-Escalation, Expansion Trial of Cytokine-Encoding Synthetic mRNA Mixture Alone or with Cemiplimab in Advanced Solid TumorsOliver Bechter, Carmen Loquai, Stephane Champiat, et al.
Pageof 7

Showing results (51-60 of 70) with videos related to

Sort By:
Pageof 7
Transplantation and Cellular Therapy|May 7, 2026
Real-World, Evidence-Based, Retrospective Study of Patients Infused with Commercially Released Lifileucel for Advanced MelanomaLilit Karapetyan, Justin Moser, Barbara T Ma, et al.
Science Immunology|May 17, 2024
LRIG1 engages ligand VISTA and impairs tumor-specific CD8<sup>+</sup> T cell responsesHieu Minh Ta, Dia Roy, Keman Zhang, et al.
The Journal of Experimental Medicine|September 9, 2015
A novel IL-17 signaling pathway controlling keratinocyte proliferation and tumorigenesis via the TRAF4-ERK5 axisLing Wu, Xing Chen, Junjie Zhao, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 2, 2025
Long-Term Efficacy and Safety of Lifileucel Tumor-Infiltrating Lymphocyte Cell Therapy in Patients With Advanced Melanoma: A 5-Year Analysis of the C-144-01 StudyTheresa Medina, Jason A Chesney, Harriet M Kluger, et al.
Journal of the American Academy of Dermatology|March 21, 2024
Germline cancer susceptibility in individuals with melanomaPauline Funchain, Ying Ni, Brandie Heald, et al.
Nature Medicine|October 16, 2023
Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trialJohn M Kirkwood, Michele Del Vecchio, Jeffrey Weber, et al.
Journal for Immunotherapy of Cancer|August 25, 2025
Efficacy and safety of one-time autologous tumor-infiltrating lymphocyte cell therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinomaRobert L Ferris, Rom S Leidner, Christine H Chung, et al.
Future Oncology (London, England)|February 23, 2024
Plain language summary of the CheckMate 76K study results: nivolumab given after stage 2B/2C melanoma is removed by surgeryJohn M Kirkwood, Michele Del Vecchio, Jeffrey Weber, et al.
Transplantation and Cellular Therapy|February 28, 2026
Advancing Cell Therapies for Solid Tumors: A Pathway to Overcome Biological, Operational, and Regulatory HurdlesKedar Kirtane, Michael Kalos, Rocky Billups, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 28, 2025
A Phase I, First-in-Human, Dose-Escalation, Expansion Trial of Cytokine-Encoding Synthetic mRNA Mixture Alone or with Cemiplimab in Advanced Solid TumorsOliver Bechter, Carmen Loquai, Stephane Champiat, et al.
Pageof 7